TRANSCEND CLL 004 Update
TRANSCEND CLL 004: 24-Mo Follow-up of Lisocabtagene Maraleucel in Relapsed/Refractory CLL/SLL

Released: December 12, 2023

Activity

Progress
1
Course Completed